Unknown

Dataset Information

0

Metabolic Profiling at COVID-19 Onset Shows Disease Severity and Sex-Specific Dysregulation


ABSTRACT:

Background

metabolic changes through SARS-CoV-2 infection has been reported but not fully comprehended. This metabolic dysregulation affects multiple organs during COVID-19 and its early detection can be used as a prognosis marker of severity. Therefore, we aimed to characterize metabolic and cytokine profile at COVID-19 onset and its relationship with disease severity to identify metabolic profiles predicting disease progression.

Material and Methods

we performed a retrospective cross-sectional study in 123 COVID-19 patients which were stratified as asymptomatic/mild, moderate and severe according to the highest COVID-19 severity status, and a group of healthy controls. We performed an untargeted plasma metabolic profiling (gas chromatography and capillary electrophoresis-mass spectrometry (GC and CE-MS)) and cytokine evaluation.

Results

After data filtering and identification we observed 105 metabolites dysregulated (66 GC-MS and 40 CE-MS) which shown different expression patterns for each COVID-19 severity status. These metabolites belonged to different metabolic pathways including amino acid, energy, and nitrogen metabolism among others. Severity-specific metabolic dysregulation was observed, as an increased transformation of L-tryptophan into L-kynurenine. Thus, metabolic profiling at hospital admission differentiate between severe and moderate patients in the later phase of worse evolution. Several plasma pro-inflammatory biomarkers showed significant correlation with deregulated metabolites, specially with L-kynurenine and L-tryptophan. Finally, we describe a strong sex-related dysregulation of metabolites, cytokines and chemokines between severe and moderate patients. In conclusion, metabolic profiling of COVID-19 patients at disease onset is a powerful tool to unravel the SARS-CoV-2 molecular pathogenesis.

Conclusions

This technique makes it possible to identify metabolic phenoconversion that predicts disease progression and explains the pronounced pathogenesis differences between sexes.

SUBMITTER: Ceballos F 

PROVIDER: S-EPMC9280146 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

2022-06-09 | ST002194 | MetabolomicsWorkbench
| S-EPMC7646225 | biostudies-literature
| S-EPMC8356725 | biostudies-literature
2022-03-01 | E-MTAB-10970 | biostudies-arrayexpress
| S-BSST416 | biostudies-other
2021-07-23 | GSE180557 | GEO
| S-EPMC7311890 | biostudies-literature
2021-04-21 | GSE172471 | GEO